To Evaluate Efficacy and Safety of Parsaclisib and Ruxolitinib in Participants With Myelofibrosis Who Have Suboptimal Response to Ruxolitinib (LIMBER-304)

Authors
Category Primary study
Registry of Trialsclinicaltrials.gov
Year 2020
The purpose of the study is to compare the efficacy and safety of parsaclisib when combined with ruxolitinb versus placebo combined with ruxolitinib in participants with myelofibrosis who have suboptimal response while receiving ruxolitinib monotherapy.
Epistemonikos ID: ddeb64e7fe671000dc955318191443e14b014cee
First added on: May 07, 2024